Medtronic's pending acquisition of Covidien will see the company's headquarters moved to Ireland, and one political hopeful is blaming the Obama Administration for chasing innovation out of the U.S.
The merger of medical device giants Medtronic and Covidien has a range of implications both for those companies and for medtech in general, former Medtronic CEO Bill Hawkins tells MassDevice.com.
By Brad Perriello and Brian Johnson
UPDATED June 16, 2014, with additional comment from Leerink Partners analyst Danielle Antalffy.
Former Medtronic (NYSE:MDT) CEO Bill George says the Covidien (NYSE:COV) deal is about more than inversion in this interview with Squawkbox on MSNBC.
Medtronic makes a big move with its $43 billion deal to acquire Covidien and its string of complementary medical device lines.
Medtronic (NYSE:MDT) said yesterday that it agreed to acquire Covidien (NYSE:COV) in a cash-and-stock deal worth nearly $43 billion.
Apollo Onyx Delivery Micro Catheter with Detachable Tip Enhances Onyx Liquid Embolic System (LES) Delivery.
FDA regulators give Covidien the stamp of approval for the company's Apollo Onyx delivery micro catheter, the 1st of its kind with a detachable tip.
Medtech giant Covidien (NYSE:COV) this week touted FDA approval for its Apollo Onyx delivery micro catheter, the 1st FDA-approved device of its kind with a detachable tip.
System monitors respiration rate, oxygen saturation and pulse rate from a single, finger sensor.